Vimarsana
Biggest News Aggregation in the World

Page 18 - Randomized Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Randomized Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Randomized Trial Today - Breaking & Trending Today

5 Ways to Fight Fatty Liver - Vimarsana News

5 Ways to Fight Fatty Liver

As we pack on the pounds, organs like our liver also gain weight. And just like elsewhere, this weight gain comes with consequences for our health.

Ivermectin for COVID? Unproven treatment stokes concern in Japan - Vimarsana News

Ivermectin for COVID? Unproven treatment stokes concern in Japan

Although the treatment has received some support from Japan's medical establishment and studies are ongoing, ivermectin is not approved as a COVID-19 remedy in the country.

Mandrola's Top 10 Cardiology Stories of 2021 - Vimarsana News

Mandrola's Top 10 Cardiology Stories of 2021

Obesity drugs had a good year, the SGLT2 inhibitors stalled, and Entresto looks less impressive -- these are some of the takes from John Mandrola, MD, in his annual review of cardiology research.

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease - Vimarsana News

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease - Vimarsana News

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...